scholarly journals Fibrinolytic properties of basidiomycetes Coprinus lagopides and Funalia trogii

2020 ◽  
Vol 215 ◽  
pp. 05003
Author(s):  
Sergei Sorokin ◽  
Mark Shamtsyan ◽  
Nicolai Petrishchev
Keyword(s):  
Side Effects ◽  
Fibrinolytic Activity ◽  
Fibrinolytic Enzymes ◽  
Two Cultures ◽  
Thrombolytic Drug ◽  
Blood Clots ◽  
Funalia Trogii

Currently, the search continues for fibrinolytic and thrombolytic drugs that quickly dissolve blood clots and do not have side effects. One of the directions of these studies is the production of fibrinolytic enzymes from deep cultures of basidiomycetes. This work examines the fibrinolytic activity of culture liquids obtained from two cultures of saprophytic basidiomycetes: Coprinus lagopides and Funalia trogii in comparison with the commercial thrombolytic drug Actilyse.

A Comparative Ex Vivo Study of Plasminogen Activators and Proteases for Fibrinolytic Activity and Side Effects in Rabbits

1977 ◽  
Vol 37 (01) ◽  
pp. 154-161 ◽  
Author(s):  
B. A Janik ◽  
S. E Papaioannou
Keyword(s):  
Side Effects ◽  
Effective Dose ◽  
Fibrinolytic Activity ◽  
Ex Vivo ◽  
Plasminogen Activators ◽  
Assay System ◽  
Coagulation Parameters ◽  
Ex Vivo Assay

SummaryUrokinase, streptokinase, Brinase, trypsin, and SN 687, a bacterial exoprotease, have been evaluated in an ex vivo assay system. These enzymes were injected into rabbits and the fibrinolytic activity as well as other coagulation parameters were measured by in vitro techniques. Dose-response correlations have been made using the euglobulin lysis time as a measure of fibrinolytic activity and the 50% effective dose has been determined for each enzyme. Loading doses, equal to four times the 50% effective dose, were administered to monitor potential toxicity revealing that Brinase, trypsin, and SN 687 were very toxic at this concentration.Having established the 50% effective dose for each enzyme, further testing was conducted where relevant fibrinolytic and coagulation parameters were measured for up to two days following a 50% effective dose bolus injection of each enzyme. Our results have demonstrated that urokinase and streptokinase are plasminogen activators specifically activating the rabbit fibrinolytic system while Brinase, trypsin and SN 687 increase the general proteolytic activity in vivo.The advantages of this ex vivo assay system for evaluating relative fibrinolytic potencies and side effects for plasminogen activators and fibrinolytic proteases have been discussed.

Screening and characterization of thermostable fibrinolytic enzyme from Bacillus amyloliquefaciens EGE-B-2d.1 / Bacillus amyloliquefaciens EGE-B-2d.1’den termostabil fibrinolitik enzimin taranması ve karakterizasyonu

2016 ◽  
Vol 41 (3) ◽  
Author(s):  
Birkan Slem ◽  
Yüksel Gezgin ◽  
Rengin Eltem
Keyword(s):  
Bacillus Amyloliquefaciens ◽  
Fibrinolytic Activity ◽  
Culture Supernatant ◽  
Specific Activity ◽  
Fibrinolytic Therapy ◽  
Fibrinolytic Enzyme ◽  
Fibrinolytic Enzymes ◽  
Enzyme Thermostability ◽  
Natural Agent

AbstractObjective: To screen fibrinolytic enzyme-producing Bacillus isolates (n=210) and to characterize of thermostable fibrinolytic enzyme from Bacillus amyloliquefaciens EGE-B-2d.1 that had the highest level of fibrinolytic activity together with the highest thermostability.Methods: Firstly, a total of 210 isolates were screened for their fibrinolytic enzyme production. The potent fibrinolytic enzyme producing isolates were evaluated for the thermostability of their fibrinolytic enzymes and one isolate showing prominent fibrinolytic activity was identified as molecular. Fermentation process was carried out on the isolate that had both the highest level of fibrinolytic activity and enzyme thermostability. The thermostable fibrinolytic enzyme from this isolate was then purified and characterized.Results: The fibrinolytic enzyme activities of 21 Bacillus sp. isolates in Nutrient Yeast Salt Medium were found to be in the range of 0.176-1.734 U/ml. The fibrinolytic activity of the enzyme purified from the culture supernatant of Bacillus amyloliquefaciens EGE-B-2d.1 was relatively stable at pH 7.0-11.0 for 24 h and also showed stability at a temperature of 60°C for 60 min. The enzyme degraded the fibrin clots by direct fibrinolysis. The specific activity and the molecular weight of the purified enzyme were estimated to be 44.46 units/mg protein and 30 kD respectively.Conclusion: The thermostable fibrinolytic enzyme from Bacillus amyloliquefaciens EGE-B-2d.1 was purified and characterized. This enzyme might also be used as a natural agent for oral fibrinolytic therapy or thrombosis prevention.

The Role of Stanozolol in the Treatment of the Postphlebitic Syndrome

1981 ◽  
Vol 26 (1_suppl) ◽  
pp. S81-S83 ◽  
Author(s):  
P. E. Jarrett
Keyword(s):  
Deep Vein Thrombosis ◽  
Side Effects ◽  
Fibrinolytic Activity ◽  
Double Blind ◽  
Vein Thrombosis ◽  
Postphlebitic Syndrome ◽  
Deep Vein ◽  
Blind Crossover Study ◽  
Double Blind Crossover Study

The postphlebitic syndrome is a result of previous deep vein thrombosis and presents with oedema, pain, induration, pigmentation and ulceration. Extravascular deposition of fibrin is associated with reduced fibrinolytic activity in these patients. In a double-blind crossover study there was evidence of benefit from stanozolol which enhanced fibrinolytic activity. No side effects of any consequence were noted with a dosage of 5 mg twice per day.

Isolation of Bacillus spp. with high fibrinolytic activity and performance evaluation in fermented douchi

2020 ◽  
Author(s):  
Jia Long ◽  
Xin Zhang ◽  
Zexin Gao ◽  
Yun Yang ◽  
Xueyi Tian ◽  
...  
Keyword(s):  
Principal Component Analysis ◽  
Molecular Biology ◽  
Fibrinolytic Activity ◽  
Principal Component ◽  
Component Analysis ◽  
Fibrinolytic Enzyme ◽  
Bacillus Velezensis ◽  
Fermentation Performance ◽  
Fibrinolytic Enzymes ◽  
Physiological And Biochemical

Fibrinolytic enzymes are effective and highly safe in treating cardiovascular and cerebrovascular diseases. Therefore, screening fibrinolytic enzyme-producing microbial strains with excellent fermentation performance is of great value to industrial applications. The fibrin plate method was used in screening strains with high yields of fibrinolytic enzymes from different fermented food products, and the screened strains were preliminarily identified using molecular biology. Then, the strains were used for the solid-state fermentation of soybeans. Moreover, the fermentation product douchi was subjected to fibrinolytic activity measurement, sensory evaluation, and biogenic amine content determination. The fermentation performance of each strain was comprehensively evaluated through principal component analysis. Finally, the target strain was identified based on strain morphology, physiological and biochemical characteristics, 16S rDNA sequence, and phylogenetic analysis results. A total of 15 Bacillus species with high fibrinolysin activities were selected. Their fibrinolytic enzyme-producing activities were higher than 5,500 IU/g. Through molecular biology analysis, we found four strains of Bacillus subtilis, 10 strains of Bacillus amyloliquefaciens, and one strain of Bacillus velezensis. The principal component analysis results showed that SN-14 had the best fermentation performance and reduced the accumulation of histamine and total amine, the fibrinolytic activity of fermented douchi reached 5,920.5 ± 107.7 IU/g, and the sensory score was 4.6 ± 0.3 (out of 5 points). Finally, the combined results of physiological and biochemical analyses showed SN-14 was Bacillus velezensis. The high-yield fibrinolytic and excellent fermentation performance strain Bacillus velezensis SN-14 has potential industrial application value.

scholarly journals Possible Risk of Thrombotic Events following Oxford-AstraZeneca COVID-19 Vaccination in Women Receiving Estrogen

2021 ◽  
Vol 2021 ◽  
pp. 1-4
Author(s):  
Ava Soltani Hekmat ◽  
Kazem Javanmardi
Keyword(s):  
Side Effects ◽  
Fish Oil ◽  
Postmenopausal Women ◽  
Birth Control ◽  
Young Women ◽  
Luteal Phase ◽  
Follicular Phase ◽  
Blood Clots ◽  
Perimenopausal Women

People who receive the ChAdOx1 nCoV-19 vaccine, particularly perimenopausal women who are on birth control or postmenopausal women who take estrogen supplements, may experience thrombosis and thrombocytopenia. Estrogen and the ChAdOx1 nCoV-19 vaccine both have the potential to cause thrombus in different ways. Some postmenopausal women who are also taking estrogens may develop thrombosis and thrombocytopenia after receiving the ChAdOx1 nCoV-19 vaccine. Therefore, women are encouraged to stop taking drugs containing estrogen before receiving this vaccine. Furthermore, consuming fish oil can help reduce the risk of developing blood clots among women who are in the luteal phase and, thus, have high estrogen levels. In addition, ChAdOx1 nCoV-19’s side effects in young women could be mitigated by administering it during the follicular phase.

scholarly journals A Few Covid Vaccine Recipients Developed a Rare Blood Disorder.

2021 ◽  
Vol 3 (8) ◽  
pp. 07-14
Author(s):  
D Grady
Keyword(s):  
Risk Factors ◽  
Side Effects ◽  
Ad Hoc ◽  
Healthcare Professionals ◽  
Blood Platelets ◽  
Expert Group ◽  
Blood Disorder ◽  
Blood Clots ◽  
Safety Committee ◽  
Low Levels

EMA’s safety committee (PRAC) has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly COVID-19 Vaccine AstraZeneca). In reaching its conclusion, the committee took into consideration all currently available evidence, including the advice from an ad hoc expert group. EMA is reminding healthcare professionals and people receiving the vaccine to remain aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within 2 weeks of vaccination. So far, most of the cases reported have occurred in women under 60 years of age within 2 weeks of vaccination. Based on the currently available evidence, specific risk factors have not been confirmed.

scholarly journals Plasminogen Activator Release After Venous Occlusion and Infusion of DDAVP

1977 ◽  
Author(s):  
M. Åberq ◽  
I.M. Nilsson
Keyword(s):  
Side Effects ◽  
Venous Thrombosis ◽  
Fibrinolytic Activity ◽  
Venous Occlusion ◽  
Thromboembolic Disease ◽  
Increased Risk ◽  
Recurrent Venous Thrombosis ◽  
Fibrinolytic Capacity ◽  
Acta Chir

Defective release of fibrinolytic activator from the. vessel walls implies an increased risk of thromboembolic disease (Isacson and Nilsson 1972). Therefore methods suitable for determination of the fibrinolytic “capacity” in man have become increasingly interesting. The fibrinolytic activity (FA) in blood after infusion of DDAVP (l-desamino-8-D-argininvasopressin) was determined in 21 normals and 42 patients with recurrent venous thrombosis. The results were compared with those found after venous occlusion (VO) in the same subjects. DDAVP induced a significant but lower increase of the fibrinolytic activity in blood than VO. The correlation was good between the FA immediately after DDAVP and VO both in normals (r = 0.53) and in patients (r = 0.63). Both DDAVP and VO induced a significantly lower FA in patients than in normals. All subjects studied showed an increase of the FA with both methods used. Both DDAVP and VO induced a significant increase of VIII:C and VIIIR:AG. This increase was about the same in the two groups. No side effects were found after infusion of DDAVP which thus seems to be suitable for determination of the fibrinolytic “capacity” in patients with thromboembolic disease.Isacson, S. and Nilsson, I.M. 1972. Acta chir. scand. 138, 313.

Effect of Ethyloestrenol on Fibrinolysis in the Vessel Wall

1975 ◽  
Author(s):  
U. Hedner ◽  
I. M. Nilsson ◽  
S. Isacson
Keyword(s):  
Side Effects ◽  
Venous Thrombosis ◽  
Plasminogen Activator ◽  
Fibrinolytic Activity ◽  
Vessel Wall ◽  
Marked Decrease ◽  
Venous Occlusion

It has been shown that phenformin plus ethyloestrenol causes a significant increase in the fibrinolytic activity of the vessel wall in most patients with recurrent idiopathic venous thrombosis and with an initially low fibrinolytic activity in the vein walls. At the same time a marked decrease in the frequency of thrombotic episodes occurred (Nilsson et al. 1974). Due to side effects of phenformin attempts have been made to administrate ethyloestrenol alone to patients with an abnormally low plasminogen activator content of the vessel wall and/or a decreased capacity to release plasminogen activator from the vein walls on venous occlusion of the arms. Ethyloestrenol in a dose of 8 mg/d has been given to 34 patients for 3 to 6 months and to 6 patients for 12 months. Ethyloestrenol caused a significant increase in the fibrinolytic activity in 30 of the 34 patients treated for 3-6 months and in 5 of those 6 treated for 12 months. Ethyloestrenol in a dose of 4 mg/d had no effect.

Fibrinolytic Activity of Two Polypeptide Chains from Human Plasminogen#

2019 ◽  
Vol 16 (4) ◽  
pp. 277-281
Author(s):  
Agustín Joison ◽  
Gustavo Baiardi ◽  
Rocío Donalisio ◽  
Federico Gallo
Keyword(s):  
Amino Acid ◽  
Fibrinolytic Activity ◽  
Sodium Borate ◽  
Isoelectric Precipitation ◽  
Fibrin Plate ◽  
Blood Clots ◽  
Human Plasminogen ◽  
Plasma Glycoprotein ◽  
Sodium Borate Buffer ◽  
Polypeptide Chains

Background: Plasminogen is a blood plasma glycoprotein of molecular weight about 92,000 Daltons. Physiologically, it incorporates into blood clots and after its activation by plasminogen activators to plasmin can perform a fibrinolytic function. Microplasmin is truncate polypeptide chain derivate of plasmin may be increase the fibrinolytic activity. Objective: To study the amino acid sequence of two polypeptides chains derivate to the plasminogen with fibrinolytic activity. Methods: he two polypeptides chains were prepared by isoelectric precipitation of human plasma in sodium borate buffer. The sample in a second step was subjected to affinity and ionic interchange chromatography and denaturalized electrophoresis was carried out on the sample previous heat 70ºC. Results: Two polypeptide chains of 29.000 and 35.000 Daltons by autolysis controlled were obtained with 25 UI of fibrinolytic activity in fibrin plate. Conclusion: Microplasmin was obtained with cleavage in different amino acid bounds and rearrangement of amino acids by autolysis with controlled alkaline precipitation.

A brief review on conventional methods for screening, product development, downstream and evaluation of fibrinolytic enzymes from marine microbes

2021 ◽  
Vol 25 (7) ◽  
pp. 194-201
Author(s):  
Devi C. Subathra ◽  
Naine S. Jemimah ◽  
Keziah S. Merlyn ◽  
V. Mohanasrinivasan
Keyword(s):  
Side Effects ◽  
High Salinity ◽  
Sea Water ◽  
Human Blood Plasma ◽  
Marine Microorganisms ◽  
Marine Microbes ◽  
Fibrinolytic Enzymes ◽  
Lighting Conditions ◽  
Microbial Enzyme ◽  
Marine Source

The ocean is a great reservoir of biodiversity and microbial metabolites. Enzymes from marine source have recently gained considerable attention as they have lower side effects and more potency when compared to other existing sources. Fibrinolytic enzymes from microbial sources possess ability to dissolve clots and help to circumvent cardiovascular problems in more efficient and safer way. The complexity of the marine environment involves high salinity, high pressure, low temperature, special lighting conditions. This contributes to the significant differences between the enzymes generated by marine microorganisms and homologous enzymes from terrestrial microorganisms leading to the boosted marine microbial enzyme technology. Further, it is believed that sea water, which is saline in nature and chemically closer to the human blood plasma, could provide biomolecules, in particular enzymes that could have lower or no toxicity or side effects when used for therapeutic applications. However, only a small proportion of fibrinolytic enzymes from marine microbiota has been examined and an even smaller proportion has been exploited. Therefore, much work needs to be done intensively and extensively in terms of potent fibrinolytic enzymes from marine resources.

Sign in / Sign up

Export Citation Format

Share Document